CSHP - California Society of Health-System Pharmacists

09/05/2025

CSHP Seminar 2025 Exhibitor Theaters Are Here!

Get ready to enhance your Seminar 2025 experience! We're excited to announce the full schedule for our Exhibitor Theaters!

These industry-led sessions offer a fantastic opportunity to dive deeper into innovative services and practical solutions. It's your chance to learn directly from experts and discover new technologies that will shape the future of pharmacy practice.

View the complete Exhibitor Theater schedule and details here: https://www.cshp.org/S25_ExhibitorTheaterPrograms

We encourage you to explore the offerings and add these compelling sessions to your Seminar 2025 itinerary!

09/04/2025

Virtual Roundtable: New California Regulations for Sterile Compounding

CSHP's Compounding Task Force is hosting a timely and informative virtual roundtable!

Join us on Tuesday, September 16, 2025, from 11:00 AM - 12:00 PM PT for a focused discussion on sterile compounding and the new California Code of Regulations that will become effective on October 1st.

This is your chance to hear from expert panelists:

• Dr. Andre Pieterse, Scripps Health
• Dr. Sam Martinez, UC San Diego Health
• Dr. Melanie Horn (Moderator), Sutter Health

After two presentations, there will be an open forum for Q&A and networking. This event is FREE and open to both CSHP members and non-members.

Register today: https://www.cshp.org/CSHP_Webinar9-16-2025

09/04/2025

CA HAN Health Advisory: Recent Rise of Mpox Cases in California and the Bay Area

The California Department of Public Health (CDPH) issued a Health Alert Network (HAN) Health Advisory regarding reports of an increase in clade II mpox cases in California. The increase of cases predominantly occurred in the San Francisco Bay Area during July and August. Most cases have occurred among gay, bis*xual, and other men who have s*x with men and their social networks.

The CDPH recommends that healthcare providers consider mpox testing for s*xually active patients with compatible signs and symptoms, regardless of vaccination status or previous infection. Mpox testing is available through most commercial laboratories and some local public health laboratories. No specific treatment for mpox has been approved, as most cases are mild and resolve with supportive care and pain management. Patients with severe or complicated mpox infections are advised to consult their infectious disease providers, CDPH, and the U.S. Centers for Disease Control and Prevention (CDC).

Vaccination for mpox consists of two doses, administered at least 28 days apart. The CDPH recommended the mpox vaccination for individuals who may be at risk for mpox to prevent severe illness, need for hospitalization, and death.

Patients who still need second doses or who may not have received the vaccine at the start of the 2022 outbreak are recommended to complete the mpox vaccine, as they are at risk for mpox. Healthcare providers should also incorporate mpox risk and vaccination status assessments at all routine s*xual health visits, especially for individuals who are gay, bis*xual, transgender, or other men who have s*x with men.

View the CA’s HAN Health Advisory here:
https://www.cdph.ca.gov/Programs/OPA/Pages/CAHAN/Recent-Rise-of-Mpox-Cases-in-California-and-the-Bay-Area.aspx

09/04/2025

Join the Fun! Trick or Treat Street at Seminar 2025! 👻✨

Bring your family and friends and join us for a spooktacular time at Trick or Treat Street during Seminar 2025!

On October 31st from 3:30 - 5:00 PM, walk around and visit our seven candy stations to collect treats and enjoy some festive fun. This is a great opportunity to connect with your colleagues and their families while celebrating the Halloween spirit.

Don't forget to wear your most creative costumes and join us at Seminar ➡️ https://www.cshp.org/Seminar2025

09/03/2025

Webinar Spotlight: "Expanding Access to OUD Treatment"

We're excited to spotlight an upcoming webinar from our affiliate chapter, the Golden Gate Society of Health-System Pharmacists (GGSHP)!

Join Dr. Tamara Lenhoff, PharmD, BCPS, on Wednesday, September 17, 2025, from 5:00 - 6:00 PM PST for a timely presentation on:

Expanding Access to OUD treatment: Understanding San Francisco’s Buprenorphine Stocking Mandate

This program will provide valuable insights for both Pharmacists and Pharmacy Technicians, covering:

The clinical significance of buprenorphine in OUD treatment.

Key provisions of the San Francisco Health Code Article 48 Amendment.

Common challenges in buprenorphine dispensing that community pharmacists may face.

This is a great opportunity to enhance your understanding of public health initiatives and medication access. The webinar offers 1 contact hour (0.1 CEU).

Register today and secure your spot ➡️ https://www.cshp.org/CSHP_Webinar9-17-2025

09/02/2025

FDA Authorizes Updated COVID Vaccines with Limitations

The U.S. Food and Drug Administration (FDA) has authorized the use of updated 2025-2026 COVID vaccines for Pfizer-BioNTech, Moderna, and Novavax, with restrictions for certain age groups and conditions. The updated 2025-2026 COVID vaccine targets the LP.8.1 strain, an offshoot of the JN.1 subvariant. The LP.8.1 strain closely matches the circulating strains that have been predominant in the United States and other regions since the beginning of 2025.

The updated 2025-2026 COVID vaccines are approved for patients aged 65 years and older. For individuals under the age of 65, the FDA has restricted the authorization of the updated 2025-2026 COVID vaccines to only include patients with at least one underlying condition that puts them at high risk for severe COVID-19.

In addition to the updated COVID vaccine approval, the FDA revoked the Emergency Use Authorization (EUA) for the COVID-19 vaccines for healthy children 11 years old and younger. The COVID-19 vaccines whose EUA has been revoked are Pfizer-BioNTech COVID-19 Vaccine, Moderna COVID-19 Vaccine, and Novavax COVID-19 Vaccine, Adjuvanted.

The currently FDA-approved COVID-19 vaccines for the 2025-2026 COVID-19 vaccine season are Comirnaty (COVID-19 Vaccine, mRNA), Mnexspike (COVID-19 Vaccine, mRNA), Nuvaxovid (COVID-19 Vaccine, Adjuvanted), and Spikevax (COVID-19 Vaccine, mRNA).

View the news release here:

The Food and Drug Administration rescinded the emergency use authorization that made COVID-19 shots available for healthy children under 5 years old.

09/01/2025

Happy Labor Day! 🌟 As we celebrate hard-working professionals everywhere, don’t forget to renew your CSHP membership and stay connected to your pharmacy community.

🎓 2025 grads: Renew as a New Practitioner Year 1 for just $40 (a $95 savings!) with code MGRAD2025.

👉 Renew today and keep advancing the profession with us!

08/31/2025

CSHP Committee Spotlight: Behind the Scenes with the Membership Committee

We're proud to feature the CSHP Membership Committee in our latest spotlight! This dedicated group of Affiliate Chapter Membership Liaisons and committed members meets monthly to strengthen our organization.

Did you know? This committee is responsible for selecting the recipients of the Affiliate Chapter Volunteer of the Year and the Affiliate Chapter Public Relations Recognition Program Award!

Recently, the committee has been hard at work supporting CSHP's growth, exploring member survey results, and defining our value proposition. Their current focus is on increasing chapter retention and engaging members not currently affiliated with a chapter.

Look for them at their booth at Seminar 2025, where they'll be ready to connect with you!

Thank you to the Membership Committee for their invaluable contributions to our community ➡️ https://bit.ly/3Vp38ra

08/31/2025

60 Days Left! Secure Your Spot for CSHP Seminar 2025 Today!

The countdown is officially on! We are now just 60 days away from the start of CSHP Seminar 2025, kicking off on October 30th! This is California's premier health-system pharmacy event, and you won't want to miss it.

Now is the perfect time to Register and Save Today! Join hundreds of your colleagues for an unparalleled experience designed to advance your practice and expand your professional network. Seminar 2025 offers:

Cutting-edge educational sessions: Stay current with the latest advancements and best practices.

Exceptional networking opportunities: Connect with leaders, peers, and mentors from across the state.

An inspiring new venue: Be among the first to experience the stunning Ga***rd Pacific Resort in Chula Vista.

And much more! (Including our Masquerade Reception, Exhibitor Theaters, and more!)

Don't let these vital 60 days slip by. Invest in your professional growth and ensure your place at this essential annual gathering.

Register for Seminar 2025 ➡️ https://www.cshp.org/Seminar2025

08/30/2025

FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’

The U.S. Food and Drug Administration (FDA) has approved a new treatment indication for a subcutaneous injection to treat serious liver disease affecting 6% of US adults. The FDA approved a new indication to expand the use of Wegovy (semaglutide) injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis (excessive scar tissue in the liver).

The efficacy of Wegovy for this new indication is being studied in one ongoing phase 3 trial with 800 clinical trial participants randomly assigned to either Wegovy (534 participants) or placebo (266 participants) in addition to lifestyle changes. Interim results showed 63% of participants receiving Wegovy had MASH resolution and no worsening of liver scarring compared to 34% of participants receiving placebo, and 37% of participants on Wegovy had improvement in liver scarring and no worsening of MASH, compared to 22% of participants receiving placebo.

Precautions and warnings for Wegovy include that people with a personal or family history of medullary thyroid cancer, patients with multiple endocrine neoplasia, type 2, or those with a known sensitivity to semaglutide or Wegovy excipients should not take Wegovy. The most common adverse reactions for Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.

View the FDA’s announcement here:
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash

08/29/2025

𝗖𝗦𝗛𝗣 𝗦𝗲𝗺𝗶𝗻𝗮𝗿 𝟮𝟬𝟮𝟱 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗼𝗻 𝗛𝗮𝘇𝗮𝗿𝗱𝗼𝘂𝘀 𝗗𝗿𝘂𝗴𝘀 & 𝗪𝗼𝗿𝗸𝗲𝗿 𝗦𝗮𝗳𝗲𝘁𝘆!

We're shining a spotlight on a highly anticipated session at CSHP Seminar 2025 that addresses a crucial topic for all healthcare professionals:

"Hazardous Drugs and Healthcare Worker Safety: Non-invasive Testing Methods for Personnel Potentially Exposed to Hazardous Drugs"

Join expert presenters Dr. Jaclyn Jaskowiak and Dr. Shirley Tsunoda for this timely discussion. This session aims to raise awareness about exploring non-invasive techniques for monitoring healthcare workers who may be exposed to hazardous drugs during their workday. Ensuring the well-being of our dedicated healthcare professionals is paramount!

Who should attend? Nurses, Student Pharmacists, New Practitioners, Pharmacy Technicians, and Pharmacists.

Session Details:
• Date: Saturday, November 1, 2025
• Time: 3:45 PM - 4:45 PM
• Track: Regulatory & Legislative
• Location: Ga***rd Pacific Resort - Chula Vista, CA

Don't miss this opportunity to gain valuable insights into protecting healthcare workers and enhancing safety protocols.

Register for CSHP Seminar 2025 today and add this essential session to your schedule ➡️ https://www.cshp.org/Seminar2025

08/28/2025

Upcoming Webinar: SBLBSHP Presents "AI Tools In Pharmacy Workflows"

We're excited to spotlight an upcoming webinar hosted by our affiliate chapter, the South Bay Long Beach Society of Health-System Pharmacists (SBLBSHP)!

Join Dr. Don Roosan, PharmD, PhD, on Wednesday, September 10, 2025, from 6:00 - 7:00 PM PST for an insightful presentation:

AI Tools In Pharmacy Workflows Empower Technicians for Safer Patient Care

This program is designed for both Pharmacists and Pharmacy Technicians and aims to provide Pharmacy Technicians opportunities and practical applications of integrating AI tools for safer patient care.

This is a fantastic opportunity to stay ahead of the curve in healthcare technology. The webinar offers 1 contact hour (0.1 CEU).

Register today and secure your spot ➡️ https://www.cshp.org/CSHP_Webinar9-10-2025